Abstracts tagged "interleukins (IL)"

Abstract Number: 1525 • 2019 ACR/ARP Annual Meeting
Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial
Christopher Ritchlin ¹, Vibeke Strand ², Rocco Ballerini ³, Richard C. Chou ⁴, Stephen Rozzo ³, Alan Mendelsohn³ and Arthur Kavanaugh ⁵, ¹Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ²Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA, Palo Alto, CA, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁵University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Tildrakizumab (TIL) is an anti–interleukin-23p19 monoclonal antibody approved by the FDA for treatment of moderate-to-severe plaque psoriasis1,2 and is under investigation for treatment of…
Abstract Number: 1526 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in a Phase 3 Study
Wendy Cantrell ¹, Patricia Lee ², Emil Tanghetti ³, Alan Mendelsohn⁴, Jeff Parno ⁴, Stephen Rozzo ⁴ and Wilson Liao ⁵, ¹Department of Dermatology, University of Alabama Birmingham, Birmingham, AL, USA; Dermatology at the Whitaker Clinic, Birmingham, AL, USA, Birmingham, AL, ²Center for Clinical Studies, Webster, TX, USA, Webster, TX, ³Center for Dermatology and Laser Surgery, Sacramento, CA, USA, Sacramento, CA, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁵Department of Dermatology, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA
Background/Purpose: We assessed residual plaque psoriasis in patients successfully treated with anti–interleukin-23p19 monoclonal antibody tildrakizumab (TIL) who interrupted treatment, relapsed, and were retreated vs continuously…
Abstract Number: 1527 • 2019 ACR/ARP Annual Meeting
Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program
Holly Glover ¹, Kristine Kucera ², Alan Mendelsohn³, Jeff Parno ³, Stephen Rozzo ³, Frank Ferritto ⁴ and Renata Block ⁵, ¹Dermatology and Skin Cancer Surgery Center, McKinney, TX, USA, McKinney, TX, ²North Texas Dermatology, Richardson, TX, USA, Richardson, TX, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴Polley Dermatology, Wilson, NC, USA, Wilson, NC, ⁵Pinski Dermatology & Cosmetic Surgery, Chicago, IL, USA, Chicago, IL
Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody with demonstrated efficacy for the treatment of chronic plaque psoriasis in a phase 2b (P05495 [NCT01225731])…
Abstract Number: 1554 • 2019 ACR/ARP Annual Meeting
Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study
Philip Mease¹, Robert B.M. Landewé ², Proton Rahman ³, Hasan Tahir ⁴, Atul Singhal ⁵, Elke Böttcher ⁶, Sandra Navarra ⁷, Aimee Readie ⁸, Shephard Mpofu ⁹, Evie Maria Delicha ⁹, Luminita Pricop ⁸ and Désirée van der Heijde ¹⁰, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Memorial University, Newfoundland, NL, Canada, ⁴Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom, ⁵Southwest Rheumatology, Dallas, TX, ⁶Rheumazentrum Favoriten, Vienna, Austria, ⁷University of Santo Tomas Hospital, Manila, Philippines, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Secukinumab (SEC) provided sustained efficacy, inhibition of radiographic progression, and stable safety profile over 52 Weeks (Wks) in patients (pts) with psoriatic arthritis (PsA)…
Abstract Number: 1768 • 2019 ACR/ARP Annual Meeting
A First-in-class Selective and Potent IRAK4 Degrader Demonstrates Robust in Vitro and in Vivo Inhibition of TLR/IL-1R Activation and Inflammation
Veronica Campbell¹, Joseph Kelleher ¹, Jesse Chen ¹, Jared Gollob ², Nan Ji ², Christine Klaus ², Christine Loh ², Michelle mayo ², Alice McDonald ², Haojing Rong ², Scott Rusin ², Kirti Sharma ², Matt Weiss ², Karen Yuan ², Duncan Walker ², Xiaozhang Zheng ², Anthony Slavin ² and Nello Mainolfi ², ¹Kymera Therapeutics, cambridge, MA, ²Kymera Therapeutics, Cambridge
Background/Purpose: IL-1R/TLR activation plays a central role in the pathophysiology of multiple autoimmune and inflammatory diseases driven by the IL-1 family of cytokines and by…
Abstract Number: 1776 • 2019 ACR/ARP Annual Meeting
Causal Effect of TNF-α, IL-12p70, IL-17 Levels on the Risk of Psoriatic Arthritis: A Mendelian Randomization Study
Dongze WU¹, Priscilla Wong ¹, Steven H.M. Lam ¹, Isaac T. Cheng ¹, Edmund K. Li ¹, Ling Qin ¹ and Lai-Shan Tam ¹, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Biologic agents targeting cytokines including TNF-α, IL-12p70 and IL-17 have been proven to be very effective in treating psoriatic arthritis (PsA). Nonetheless, whether these…
Abstract Number: 1821 • 2019 ACR/ARP Annual Meeting
Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain
Ana-Maria Orbai ¹, Rocco Ballerini ², Richard C. Chou ³, Stephen Rozzo ², Alan Mendelsohn² and Luis R. Espinoza ⁴, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ³University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁴Section of Rheumatology, LSU Health Sciences Center, New Orleans, LA, New Orleans, LA
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved to treat moderate-to-severe plaque psoriasis. A randomized, double-blind, multidose, placebo (PBO)-controlled, phase 2b study (NCT02980692)…
Abstract Number: L17 • 2018 ACR/ARHP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Christopher T. Ritchlin¹, Arthur Kavanaugh², Joseph F. Merola³, Georg Schett⁴, Jose U. Scher⁵, Richard B. Warren⁶, Deepak Assudani⁷, Thomas Kumke⁸, Barbara Ink⁷ and Iain B. McInnes⁹, ¹University of Rochester Medical Centre, Rochester, NY, ²UC San Diego School of Medicine, La Jolla, CA, ³Brigham and Women's Hospital Harvard Medical School, Boston, MA, ⁴Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, ⁵Department of Medicine, NYU Langone Medical Center, New York, NY, ⁶The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹University of Glasgow, Glasgow, United Kingdom
Background/Purpose: IL-17F shares structural homology and overlapping biologic function with IL-17A. In vitro studies demonstrate that IL-17F has biologic effector function that can modulate inflammation.…
Abstract Number: 991 • 2018 ACR/ARHP Annual Meeting
Critical Role of Interleukin-1α (IL-1α) in IL-1β-Induced Inflammatory Responses: Cooperation with NF-κBp65 in Transcriptional Regulation
Anil K. Singh¹, Sabrina Fechtner¹, Mukesh Chourasia², Jerry Sicalo¹ and Salahuddin Ahmed¹, ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ²Department of Pharmacoinformatics,, National lnstitute of Pharmaceutical Education and Research, Hajipur,, India
Background/Purpose: Interleukin-1β (IL-1β) and IL-1α are cytokines of IL-1 family that orchestrate acute and chronic inflammatory diseases. However, their distinct role or the extent of…
Abstract Number: 2801 • 2018 ACR/ARHP Annual Meeting
A Novel B-Cell-Helper IL-21-Producing CD8+ T Cell Subset Involved in the Pathogenesis of Rheumatoid Arthritis
Kazuhiko Higashioka¹, Masahiro Ayano¹, Yasutaka Kimoto², Hiroki Mitoma¹, Mitsuteru Akahoshi¹, Yojiro Arinobu¹, Koichi Akashi¹, Takahiko Horiuchi³ and Hiroaki Niro⁴, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: A plethora of evidence from genome-wide association studies and relevant animal models implicates a pivotal role of T cells in the pathogenesis of rheumatoid…
Abstract Number: 1659 • 2018 ACR/ARHP Annual Meeting
Sustained Improvements in Physical Function, Quality of Life, and Work Productivity after Ixekizumab Therapy in Patients with Active Psoriatic Arthritis: 3-Year Results
Roy Fleischmann¹, Vinod Chandran², Eric Lespessailles³, Julie Birt⁴, Olivier Benichou⁴, Janelle Erickson⁴ and Catherine Shuler⁴, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Krembil Research Institute and University of Toronto, Toronto, ON, Canada, ³University of Orléans, Orléans, France, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Ixekizumab (IXE), a high-affinity mAb that selectively targets IL-17A, has shown improvements compared to placebo not only in disease activity but also in various…
Abstract Number: 2021 • 2018 ACR/ARHP Annual Meeting
Th22 Cells in Peripheral Blood and Synovial Fluid of Patients with Enthesitis Related Arthritis
Sandeep Kansurkar¹, Ankita Singh², Ramnath Misra³ and Amita Aggarwal³, ¹Dept of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: IL-17 and IL-22 are important cytokines in pathogenesis of spondyloarthropathy. In an IL-23 or IL-22 over-expressing mouse model it was shown that enthesitis is…
Abstract Number: 2022 • 2018 ACR/ARHP Annual Meeting
Evidence of Inflammation Amplification By Interleukin-6 and Interleukin-17A in Synovial Compartment of Juvenile Idiopathic Arthritis – Enthesitis Related Arthritis
Rutviz Mistry¹, Sandeep Kumar¹, Sanjukta Majumder², Sandeep Kansurkar³, Amita Aggarwal¹ and Ramnath Misra¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Dept of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: F759 mice with single amino-acid substitution in IL-6 receptor gp130 (Y759F) develops features of autoimmune disorders like arthritis, multiple sclerosis due to IL-17A and IL-6…
Abstract Number: 2411 • 2018 ACR/ARHP Annual Meeting
The Ovarian Reserve Measuring the Anti-Müllerian Hormone Is Not Diminished in Patients with Rheumatoid Arthritis Compared to the Healthy Population
Mireia López-Corbeto¹, Sara Marsal¹, Andrea Pluma², Sergio Martinez², Maria Lopez-Lasanta², Agusti Sellas-Fernandez², Juan José de Agustín² and Mireia Barcelo², ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: Rheumatoid Arthritis (RA) is the most prevalent chronic inflammatory arthritis, affecting 0.5-1% worldwide population and predominates in females. Altered fertility has been reported due…
Abstract Number: 2556 • 2018 ACR/ARHP Annual Meeting
Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial
Helena Marzo-Ortega¹, Joachim Sieper², Alan J. Kivitz³, Ricardo Blanco⁴, Martin Cohen⁵, Evie Maria Delicha⁶, Susanne Rohrer⁶ and Hanno Richards⁶, ¹NIHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom, ²University Clinic Benjamin Franklin, Berlin, Germany, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵McGill University, Montreal, QC, Canada, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody that neutralizes IL-17A, has shown significant and sustained improvement in the signs and symptoms of active ankylosing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].